Pfizer's stock has recently struggled but remains a bargain with generous dividends. Is now a good time to invest in PFE?

With the market underpricing its earnings stability and future catalysts, Pfizer presents a compelling defensive investment ...

Healthcare stocks have been out of vogue with investors since late 2022. Myriad reasons underlie the negative sentiment ...

Pfizer (PFE) faces allegations from Senator Ron Wyden (D-Ore.) of running the largest tax-avoidance scheme in Big Pharma.

Senator Ron Wyden (D-Ore.), a senior member of the Senate Finance Committee, accused Pfizer (PFE) of carrying out what he ...

Sen. Ron Wyden and other Democrats claim Pfizer used a "colossal" scheme to avoid paying billions in U.S. taxes.

Few companies embody the term 'pharma giant' as much as Pfizer. Here we take a look at the colourful history of one of the biggest drugmakers in the world. Pfizer was founded in 1849 by two recent ...

The ongoing investigation by Wyden and his Democratic compatriots from the Finance Committee has pointed the finger at ...

Pfizer's $25 support holds strong, with institutional buying signals and growth potential in oncology. Click here to read an ...

Pfizer offers a substantial 6.7% dividend yield and has increased its dividend for 16 consecutive years. The stock trades at a forward P/E of just 8.7, close to historical lows. Despite policy ...